Randeep Gill

Learn More
BACKGROUND Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer's disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is(More)
TPS163 Background: While anti-EGFR monoclonal antibody, CET, improves survival in KRAS WT chemotherapy refractory aCRC, dual biologic strategies may overcome observed resistance to therapy. BRIV is a tyrosine kinase inhibitor of the vascular endothelial and fibroblast growth factor receptors (VEGFR/FGFR). This study is designed to assess the added benefit(More)
  • 1